Advertisement
U.S. markets closed

Xeris Biopharma Holdings, Inc. (XERS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.0400-0.1400 (-4.40%)
At close: 04:00PM EST
3.0400 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close3.1800
Open3.2400
Bid3.1400 x 2200
Ask3.1500 x 2900
Day's Range3.0300 - 3.2500
52 Week Range1.1300 - 3.2600
Volume2,595,835
Avg. Volume2,118,890
Market Cap419.9M
Beta (5Y Monthly)1.21
PE Ratio (TTM)N/A
EPS (TTM)-0.4600
Earnings DateMar 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XERS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xeris Biopharma Holdings, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/21/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    12 days agoArgus Research
View more
  • Business Wire

    Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

    CHICAGO, February 28, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that

  • Business Wire

    Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

    CHICAGO, February 05, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:00 am Eastern Time. To access the presentation, please

  • Zacks

    Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza

    Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.